On March 1, 2024, the Office of Information and Regulatory Affairs (“OIRA”), Office of Management and Budget (“OMB”), Executive Office of the President
received the final version of FDA’s rule on regulation of laboratory developed tests (“LDTs”) for administrative review. Having swiftly moved to OIRA review in under 5-months from the publication of the
proposed rule and under 3-months from the end of its comment period, the rule has undoubtedly been a top priority for the FDA. Further, as of the date of this post, OIRA has
scheduled four back-to-back meetings with interested stakeholders, all of which are to be held the week of March 18th. All of this signals that the final rule remains on track for potential issuance in April 2024, the target date for final action on the rule as we previously discussed
here.
[View source.]